NCT03724877

Effectiveness of Triple Therapy in COPD

Comparative Effectiveness of Triple Therapy in COPD: A New-user Cohort Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 8,853 (actual)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: All
• Age: 55 Years
• Healthy volunteers: Not accepted

Summary

To assess the effectiveness of maintenance treatment of Chronic obstructive pulmonary disease (COPD) with the Long-acting beta2-agonist - long-acting muscarinic antagonists-inhaled corticosteroids (LABA-LAMA-ICS) combination with a LABA-LAMA combination on the risk of COPD exacerbation and the safety on the incidence of community acquired pneumonia.

Conditions

• Pulmonary Disease, Chronic Obstructive

Interventions

Type	Name	Description
DRUG	Long-acting beta2-agonist-long-acting muscarinic antagonists-inhaled corticosteroids(LABA-LAMA-ICS)	(LABA-LAMA-ICS)
DRUG	Long-acting beta2-agonist-inhaled corticosteroids-long-acting muscarinic antagonists (LABA-LAMA)	(LABA-LAMA)

Timeline

• Start date: 2018-11-10
• Primary completion: 2018-11-12
• Completion: 2018-11-12
• First posted: 2018-10-30
• Last updated: 2019-12-03
• Results posted: 2019-12-03

Locations

1 site across 1 country: United Kingdom